LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Gilead Sciences Inc.

Fechado

SetorSaúde

109.92 -1.08

Visão Geral

Variação de preço das ações

24h

Atual

Mín

109.88

Máximo

110.58

Indicadores-chave

By Trading Economics

Rendimento

-468M

1.3B

Vendas

-902M

6.7B

P/E

Médio do Setor

22.557

53.54

EPS

1.81

Rendimento de Dividendos

2.94

Margem de lucro

19.724

Funcionários

17,600

EBITDA

-504M

2.6B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+9.44% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

2.94%

2.44%

Próximos Ganhos

7 de ago. de 2025

Próxima data de dividendos

27 de jun. de 2025

Próxima data de ex-dividendo

13 de jun. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.2B

134B

Abertura anterior

111

Fecho anterior

109.92

Sentimento de Notícias

By Acuity

65%

35%

328 / 381 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Gilead Sciences Inc. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de abr. de 2025, 20:17 UTC

Ganhos

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

11 de fev. de 2025, 21:17 UTC

Ganhos

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

27 de abr. de 2025, 11:00 UTC

Principais Notícias

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

24 de abr. de 2025, 20:08 UTC

Ganhos

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences 1Q Rev $6.67B >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences: During 1Q Generated $1.8 Billion in Operating Cash Flow >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences: 1Q Lower Veklury (Remdesivir) and Oncology Sales Offset by Higher HIV and Liver Disease Sales >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences Sees 2025 EPS $5.65-EPS $6.05 >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences 1Q EPS $1.04 >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences 1Q EPS $1.04 >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences Sees FY EPS $5.65-EPS $6.05 >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences 1Q Total Liver Disease Sales $758M >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences 1Q Net $1.32B >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences Sees FY Adj EPS $7.70-Adj EPS $8.10 >GILD

24 de abr. de 2025, 20:02 UTC

Ganhos

Gilead Sciences 1Q Rev $6.7B >GILD

11 de abr. de 2025, 09:30 UTC

Principais Notícias

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

19 de mar. de 2025, 14:50 UTC

Principais Notícias

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28 de fev. de 2025, 12:00 UTC

Principais Notícias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 de fev. de 2025, 22:13 UTC

Conversa de Mercado
Ganhos

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11 de fev. de 2025, 21:06 UTC

Ganhos

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences Raises Dividend 2.6%>GILD

Comparação entre Pares

Variação de preço

Gilead Sciences Inc. Previsão

Preço-alvo

By TipRanks

9.44% parte superior

Previsão para 12 meses

Média 120.47 USD  9.44%

Máximo 140 USD

Mínimo 92 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para Gilead Sciences Inc. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

20 ratings

15

Comprar

5

Manter

0

Vender

Pontuação Técnica

By Trading Central

97.33 / 103.17Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

328 / 381 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.